Morgan Stanley Rates Qiagen (QGEN) buy, $42 Price Target

Morgan Stanley analyst Steve Beuchaw raises QGEN's rating to Buy, targeting $42, a 8.44% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 2:01 PM EDT · Updated Jun 26, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Morgan Stanley rated Qiagen N.V. ($QGEN) "buy" with a $42 price target on June 23, 2026.

Since the rating, $QGEN is up 5.1% after 1 week, up 12.4% after 1 month and up 25.1% to date (from the $36.87 close on Jun 23, 2026).

QGEN Qiagen N.V.

$46.13 +2.99% year to date

Daily close · Oct 16, 2026

Key Points

Morgan Stanley's Steve Beuchaw upgraded QGEN to a Buy rating with a new price target of $42 on June 23, 2026.
Morgan Stanley's $42 price target implies 8.44% upside from Qiagen N.V.'s ($QGEN) current $38.73 share price.
Shares of QGEN traded at $36.28 on Tuesday, as the company witnessed insider selling activity in August 2025.
Institutional investors like Wellington Management and BlackRock increased their QGEN holdings, while Deutsche Bank reduced its position.

Get $QGEN trade alerts by text

We text you when insiders, Congress or big funds trade $QGEN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Qiagen N.V. alert may contain errors. Disclosures

Morgan Stanley analyst Steve Beuchaw has upgraded QGEN to a Buy rating, setting a new price target of $42. This change was announced on June 23, 2026. Shares of QGEN traded at $36.28 on Tuesday.

Analyst rating track record

Morgan Stanley vs. the S&P 500

YTD return +29.92% hypothetical

All-time return +26.54% S&P 500 +33.10%

vs. S&P 500 -6.56% behind the index

Hypothetical returns from Morgan Stanley's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in QGEN

Several institutional investors have been active in QGEN recently. Wellington Management Group increased its holdings by 933,394 shares, bringing its total to about 14.36 million shares valued at approximately $575.1 million, a 6.9% increase. Price T Rowe Associates also added 421,381 shares, ending with about 8.43 million shares worth $337.5 million, marking a 5.3% rise. Vanguard Capital Management opened a new position with 6.11 million shares valued at $247.4 million. On the other hand, Deutsche Bank AG reduced its stake by 1,910,454 shares, now holding about 5.6 million shares worth $224.3 million, a decrease of 25.4%. BlackRock, Inc. slightly increased its position by 117,495 shares, reaching 5.25 million shares valued at $210.2 million.

Insider Buying and Selling at Qiagen N.V.

In August 2025, several insiders at QGEN sold shares. Roland Sackers sold 31,423 shares at an average price of $49.21 on August 15, and another 18,577 shares at $49.00 on August 14. Thierry Bernard also sold 25,000 shares at $48.80 on August 15. These transactions were not part of a planned sale.

Analysts Set New Price Targets

On June 23, 2026, Morgan Stanley upgraded QGEN to a Buy rating with a $42 price target. Previously, Stifel maintained a Hold rating with a $36 target on May 18, 2026. TD Cowen also maintained a Hold with a $40 target on May 7, 2026. JP Morgan maintained a Buy rating with a $45 target on April 29, 2026.

Bottom Line

Morgan Stanley's upgrade of QGEN to a Buy with a $42 target highlights growing optimism among analysts. Institutional investors are also adjusting their stakes, with some increasing their holdings while others reduce. Insider sales in 2025 suggest some executives were cashing in at higher prices. As always, these filings are backward-looking and may not reflect the current state of affairs.

12-month forecast